107 related articles for article (PubMed ID: 10613749)
1. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.
Xiong X; Yang H; Westland CE; Zou R; Gibbs CS
Hepatology; 2000 Jan; 31(1):219-24. PubMed ID: 10613749
[TBL] [Abstract][Full Text] [Related]
2. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
Xiong X; Flores C; Yang H; Toole JJ; Gibbs CS
Hepatology; 1998 Dec; 28(6):1669-73. PubMed ID: 9828233
[TBL] [Abstract][Full Text] [Related]
3. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
[TBL] [Abstract][Full Text] [Related]
4. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
[TBL] [Abstract][Full Text] [Related]
5. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
7. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
León P; Pozo F; Echevarría JM
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
[TBL] [Abstract][Full Text] [Related]
8. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
[TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
[TBL] [Abstract][Full Text] [Related]
10. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.
Aye TT; Bartholomeusz A; Shaw T; Bowden S; Breschkin A; McMillan J; Angus P; Locarnini S
J Hepatol; 1997 May; 26(5):1148-53. PubMed ID: 9186847
[TBL] [Abstract][Full Text] [Related]
12. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.
Stuyver L; Van Geyt C; De Gendt S; Van Reybroeck G; Zoulim F; Leroux-Roels G; Rossau R
J Clin Microbiol; 2000 Feb; 38(2):702-7. PubMed ID: 10655370
[TBL] [Abstract][Full Text] [Related]
13. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
15. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
[TBL] [Abstract][Full Text] [Related]
16. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
17. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
Seignères B; Pichoud C; Ahmed SS; Hantz O; Trépo C; Zoulim F
J Infect Dis; 2000 Apr; 181(4):1221-33. PubMed ID: 10762559
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
19. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
Melegari M; Scaglioni PP; Wands JR
Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
